Veracyte. has filed a patent for methods, systems, and kits to identify homologous recombination deficiency prostate cancer in a subject. The patent includes biomarkers, genomic classifiers, and bioinformatic methods for diagnosis and prognosis. It also covers predicting response to anticancer therapy based on expression analysis. GlobalData’s report on Veracyte gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Veracyte Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Veracyte, ML-based biomarker screening was a key innovation area identified from patents. Veracyte's grant share as of January 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.

Diagnosis and treatment of homologous recombination deficiency prostate cancer

Source: United States Patent and Trademark Office (USPTO). Credit: Veracyte Inc

A patent application (Publication Number: US20240002944A1) outlines a method for diagnosing and treating prostate cancer based on the expression levels of specific nucleic acid targets. The method involves obtaining a biological sample from a subject with prostate cancer, detecting the expression levels of targets listed in Table 6 or Table 7, and prognosing the patient with homologous recombination deficiency prostate cancer. If the patient is determined to have this type of cancer, treatment with a PARP inhibitor is recommended. Additionally, the method includes administering alternative anti-cancer treatments if the expression levels indicate the absence of homologous recombination deficiency prostate cancer, such as surgery, chemotherapy, or immunotherapy.

Furthermore, the patent application describes a kit for identifying, diagnosing, and prognosing prostate cancer in a subject. The kit includes agents for detecting the presence or expression levels of specific targets, reagents for various detection methods like in situ hybridization or PCR-based methods, and probes capable of hybridizing to target nucleic acids. The kit also provides information on determining the subject's responsiveness to anti-cancer therapy and includes control reference samples for accuracy. Additionally, a probe set and system for analyzing prostate cancer are detailed, incorporating a computer model for determining the presence of homologous recombination deficiency prostate cancer based on nucleic acid expression levels. Overall, the patent application offers a comprehensive approach to diagnosing and treating prostate cancer based on specific gene expression patterns.

To know more about GlobalData’s detailed insights on Veracyte, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies